Elevai Labs, Inc. (NASDAQ:ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop
Leading biopharmaceutical company taps AWS and Accenture for technology modernizationAt AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today announced it is working with
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today
Non-invasive genomic test is designed to help physicians guide next steps for current and former smokers with lung nodulesVeracyte, Inc. (NASDAQ:VCYT) announced that clinical validation data published in the journal
Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess
Primary endpoint metDemonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical Study Report available
ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulationsBreast cancer cryoablation is already performed in India with